Drug intelligence / Profile preview

GSK223192A

Development stage: Phase 2
Lead developer: GSK
Modality: Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

GSK223192A is an investigational hepatitis B vaccine developed by GSK Biologicals. It is a recombinant protein subunit vaccine containing the hepatitis B surface antigen (HBsAg) formulated with a proprietary Adjuvant System. The vaccine was designed to evaluate the impact of different adjuvant systems on the immune response compared to established vaccines like Engerix-B and Fendrix. It was primarily studied in Phase 2 clinical trials (e.g., NCT00805389) to assess safety and immunogenicity in healthy adults and potentially immunocompromised populations.

Other names: Hepatitis B vaccine (GSK223192A)

Targets

HBsAg (Hepatitis B surface antigen)

Beyond the preview

Go deeper on GSK223192A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GSK223192A.

Explore the full profile